Drug Trial Radar · NCT04870333
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Last checked: Nov 19, 2026Latest source record: Jun 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,240
Actual
Start
Feb 19, 2021
Primary completion
Apr 16, 2025
Study completion Apr 16, 2025
Sponsor
- Lead sponsor
- Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Life Arc; Kidney Research UK (KRUK); UNION therapeutics; Addenbrookes Charitable Trust; GlaxoSmithKline; National Institute for Health Research, United Kingdom
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis. Although vaccines are now available, there remains a need for other prophylactic agents until vaccine use becomes widespread globally and effectiveness and durability is established, particularly in immunocompromised individuals, for whom vaccine responses may be suboptimal. Efforts are underway to repurpose established drugs with well understood drug interactions and safety profiles. PROTECT-V is a platform trial to test prophylactic interventions against SARS-CoV2 infection in vulnerable patient populations at particularly high risk of COVID-19 and its complications, seeking to identify treatments that either might prevent the disease from occurring or may reduce the number of cases where the disease becomes serious or life-threatening. In PROTECT-V, multiple agents can be evaluated on the same platform across vulnerable populations, with the option of adding additional treatments at later time points as these become available. The expectation is for as many sites as possible to recruit to all available trial treatments at any time, however, the platform structure and randomisation/data collection systems allow sites to open the trial treatment arms according to their capacity. The trial opened with intranasal niclosamide and matched placebo, aiming to recruit 1500 vulnerable renal patients in February 2021. A parallel study protocol, was conducted in India, sponsored by The George Institute. Recruitment of around 750 Indian patients was completed in with the rest of the study arm recruitment in November 2022. The Niclosamide arm of the study was completed in June 2023. The second agent, intranasal and inhaled ciclesonide and matched placebo, was meant to be added to the platform in mid-2022 in the same renal patient population however it was unable to be included due to other factor. Sotrovimab and matched placebo have been added to the platform in August 2022 which aim to recruit approximately 800-1000 patients from the main study population with additional patient groups with primary immunodeficiency, any Haematology or Oncology patient who is currently receiving or has received chemotherapy or who is immunocompromised as a result of their disease or treatment, those with a diagnosis of an autoimmune or inflammatory disease receiving immunosuppression and also haematopoietic stem cell transplant recipients.
Conditions
- Covid19
Interventions
NiclosamideDrug
140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
PlaceboDrug
140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
CiclesonideDrug
Participants will be prescribed ciclesonide once daily, administered as follows: Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
PlaceboDrug
Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
SotrovimabDrug
There will be a single infusion of sotrovimab administered at the beginning of the study. 500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose.
PlaceboDrug
There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed symptomatic COVID-19 infection during treatmentTime frame: 6-9 months. Reported at 24 weeks for niclosamide and ciclesonide arms and 12 weeks for sotrovimab arm from date of IMP administration.
Locations
45 sites in 1 country. Site status is shown where the registry gives one.
NHS Lanarkshire - University Hospital Monklands
Airdrie, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Betsi Cadwaladr University Health Board
Bodelwyddan, United Kingdom
Brighton and Sussex University Hospitals NHS Trust
Brighton, United Kingdom
North Bristol NHS Trust
Bristol, United Kingdom
West Suffolk NHS Foundation Trust
Bury St Edmunds, United Kingdom
Royal Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom
East Kent Hospitals University NHS Foundation Trust
Canterbury, United Kingdom
Cardiff & Vale University Health Board
Cardiff, United Kingdom
Epsom and St Helier University Hospitals NHS Trust
Carshalton, United Kingdom
Ayrshire & Arran NHS Trust
Crosshouse, United Kingdom
Dartford and Gravesham NHS Trust
Dartford, United Kingdom
University Hospitals of Derby and Burton NHS Trust
Derby, United Kingdom
Dorset County Hospital NHS Foundation Trust
Dorchester, United Kingdom
NHS Tayside
Dundee, United Kingdom
The Royal Devon and Exeter NHS Foundation Trust
Exeter, United Kingdom
James Paget University Hospital NHS Foundation Trust
Great Yarmouth, United Kingdom
Hull University Teaching Hospitals NHS Trust
Hull, United Kingdom
Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust
Kings Lynn, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Liverpool, United Kingdom
Barts Health NHS Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
King's College Hospital NHS Foundation Trust
London, United Kingdom
Royal Free NHS Foundation Trust
London, United Kingdom
St George's University Hospitals NHS Foundation Trust
London, United Kingdom
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Wirral University Teaching Hospital NHS Foundation Trust
Metropolitan Borough of Wirral, United Kingdom
South Tees Hospitals NHS Foundation Trust
Middlesbrough, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
North West Anglia NHS Foundation Trust
Peterborough, United Kingdom
University Hospitals Plymouth NHS Trust
Plymouth, United Kingdom
Portsmouth Hospitals NHS Trust
Portsmouth, United Kingdom
Royal Berkshire NHS Foundation
Reading, United Kingdom
Salford Royal NHS Foundation
Salford, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
The Shrewsbury and Telford Hospital NHS Trust
Shrewsbury, United Kingdom
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.